Literature DB >> 6267205

Characterization of receptors for cholecystokinin and related peptides in mouse cerebral cortex.

A Saito, I D Goldfine, J A Williams.   

Abstract

The characteristics of cholecystokinin (CCK) binding to its receptors in a particulate membrane fraction of mouse cerebral cortex were studied by employing biologically active radioiodinated CCK prepared by conjugation with 125I-Bolton-Hunter (125I-BH) reagent. At 24 degrees C binding was rapid, reversible, and linearly related to protein content. Binding was maximal at acidic pH (6.5) and reduced by the presence of monovalent cations. Under physiological conditions (pH 7.4, 118 mM-NaCL, 4.7 mM-KCl) Scatchard plots of CCK binding were linear with a KD value of 1.27 nM and binding capacity of 115 fmol/mg protein. Optimal binding required the presence of both Mg2+ and EGTA, and was inhibited by the addition of micromolar concentrations of Cu2+ (ID50 = 30 microM). The cortical receptor recognized all major forms of CCK, with an order of potency of: cholecystokinin octapeptide (CCK8) greater than CCK greater than cholecystokinin tetrapeptide (CCK4). Desulfated cholecystokinin octapeptide (dCCK8) had a 10-fold lower affinity than CCK8. Dibutyryl cyclic GMP, a potent competitive inhibitor of CCK binding to receptors in pancreas, was not a specific inhibitor of CCK binding to brain receptors. These present results support the concept that CCK may function as a regulatory peptide in brain, and that the cortical CCK receptor is different from the receptors mediating the peripheral action of CCK.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6267205     DOI: 10.1111/j.1471-4159.1981.tb00481.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  12 in total

1.  Pharmacological characterization of RP 62203, a novel 5-hydroxytryptamine 5-HT2 receptor antagonist.

Authors:  A Doble; D Girdlestone; O Piot; D Allam; J Betschart; A Boireau; A Dupuy; C Guérémy; J Ménager; J L Zundel
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

2.  Activation of amygdala cholecystokininB receptors potentiates the acoustic startle response in the rat.

Authors:  P W Frankland; S A Josselyn; J Bradwejn; F J Vaccarino; J S Yeomans
Journal:  J Neurosci       Date:  1997-03-01       Impact factor: 6.167

3.  Evidence for a common evolutionary origin of brain and pancreas cholecystokinin receptors.

Authors:  S R Vigna; M C Thorndyke; J A Williams
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

4.  G protein-coupled cholecystokinin-B/gastrin receptors are responsible for physiological cell growth of the stomach mucosa in vivo.

Authors:  A Nagata; M Ito; N Iwata; J Kuno; H Takano; O Minowa; K Chihara; T Matsui; T Noda
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-15       Impact factor: 11.205

5.  Cyclic cholecystokinin analogues with high selectivity for central receptors.

Authors:  B Charpentier; D Pelaprat; C Durieux; A Dor; M Reibaud; J C Blanchard; B P Roques
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

6.  Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist.

Authors:  R S Chang; V J Lotti
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

Review 7.  The production and role of gastrin-17 and gastrin-17-gly in gastrointestinal cancers.

Authors:  Jeffrey Copps; Richard F Murphy; Sándor Lovas
Journal:  Protein Pept Lett       Date:  2009       Impact factor: 1.890

8.  Characterization of [3H]cholecystokinin octapeptide binding to mouse brain synaptosomes: effects of neuroleptics.

Authors:  Y Hama; M Ebadi
Journal:  Neurochem Res       Date:  1987-08       Impact factor: 3.996

9.  CCKB receptor activation reduces glutamate-induced depolarization in slices of rat cerebral cortex.

Authors:  J Harro; P Westerling; L Oreland
Journal:  J Neural Transm Gen Sect       Date:  1993

10.  Induced association of mu opioid (MOP) and type 2 cholecystokinin (CCK2) receptors by novel bivalent ligands.

Authors:  Yaguo Zheng; Eyup Akgün; Kaleeckal G Harikumar; Jessika Hopson; Michael D Powers; Mary M Lunzer; Laurence J Miller; Philip S Portoghese
Journal:  J Med Chem       Date:  2009-01-22       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.